Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 2,752 shares at $11.23 ($30K) on 2023-03-02, disclosed to the SEC on 2023-03-03.
Scheduled sale ($30k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.46 | 1,602 | $17K | 55.8% |
| 2 | $11.23 | 145 | $2K | 5.4% |
| 3 | $11.60 | 1,005 | $12K | 38.8% |
| Total | $10.92 avg | 2,752 | $30K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |